Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Epoxides Stories

2009-10-06 10:53:00

NEW YORK, Oct. 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Propylene Glycol: 2009 World Market Outlook And Forecast http://www.reportlinker.com/p0152025/Reportlinker-Adds-Propylene-Glycol-2009-World-Market-Outlook-And-Forecast.html The report analyzes worldwide markets for Propylene glycol, including Europe, Asia, North America, Latin America and Oceania. It provides the most complete and current...

2009-04-27 07:18:00

FAIRFIELD, N.J., April 27 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company launched Centany(R) (mupirocin ointment, 2%) and Uramaxin(TM) (20% Urea) Foam to its core Dermatology and Podiatry physician audiences. Centany(R) received a New Drug Approval in December 2002 and is patented through 2018. Centany(R) represents a significant step in Medimetriks' plan to commercialize patent-protected therapies that offer important patient benefits. Uramaxin(TM) Foam...

2009-01-12 07:00:00

Spiriva Will Remain the Gold Standard Treatment Through 2017, According to a New Report from Decision Resources. WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a biologic drug that is superior to Boehringer Ingelheim/Pfizer's Spiriva in reducing yearly COPD-related exacerbations would earn a higher patient share in Europe (30 percent) than in the U.S. (15 percent)...

2008-10-06 09:00:09

Pfizer Canada and Boehringer Ingelheim, a German drug company, have announced positive results of the Uplift trial, which showed that when patients with chronic obstructive pulmonary disease received tiotropium, there was a statistically significant 16% decrease in the risk of death. The study showed sustained improvements in lung function for up to four years (p Tiotropium, a long-acting inhaled anticholinergic medication, also provided statistically significant improvements in...

2008-10-05 09:00:05

RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNewswire/ -- Results of the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) trial, showed that SPIRIVA(R) HandiHaler(R) (tiotropium bromide inhalation powder), sustained improvements in lung function for up to 4 years as measured by FEV(1) (p UPLIFT, one of the largest COPD trials ever undertaken, is a four-year multicenter (470 sites), multinational (37 countries), randomized, double-blind, placebo-controlled,...

2008-09-24 21:00:09

Anticholinergic drugs contained in the inhalers could increase the risk of a heart attack, cardio-vascular death or stroke by more than 50 per cent, research showed.The inhalers help people with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, to breathe. They open up airways by relaxing muscles, to allow air in and out of the patient's lungs more easily.The latest study looked at the inhalers ipratropium (Atrovent) and tiotropium (Spiriva). The...

2008-09-24 18:00:14

Inhaled anti-cholinergic agents by patients with chronic obstructive pulmonary disease is linked to increased risk of heart attack, U.S. researchers said. Inhaled anti-cholinergic agents -- including ipratropium bromide or tiotropium bromide -- are widely used in patients with COPD. Inhaled tiotropium is the most widely prescribed medication for COPD, with more than 8 million patients worldwide having used it since its approval in 2002, said Dr. Sonal Singh of Wake Forest University School...

2008-09-24 06:00:09

By Rita Rubin Widely prescribed drugs recommended as first-line therapy for chronic obstructive pulmonary disease, or COPD -- the USA's fourth-leading killer -- raise the risk of heart attacks, strokes and death from heart disease, a study suggests. COPD refers to two incurable lung ailments, chronic bronchitis and emphysema. Most COPD patients have both. The most common cause is cigarette smoking. Researchers pooled the results of 17 clinical trials of 14,783 patients that...

2008-09-04 00:00:05

Shares of Forest Laboratories Inc. fell to a seven-year low Wednesday following disappointing results from two late-stage trials of Forest's drug candidate aclidinium bromide. In both trials, the drug met its primary goal of improving lung function for patients with moderate to severe chronic obstructive pulmonary disease. But in each trial, the drug missed one of its secondary goals. Forest said aclidinium bromide was not as effective as it had been in other tests, and analysts suggested a...

2006-09-04 11:53:46

NEW YORK (Reuters Health) - An ointment containing the antibiotic mupirocin does not speed healing or prevent infection when applied to clean surgical wounds before the wound is sealed, research suggests. In fact, the ointment may increase the risk of skin edge necrosis (death), an Australian research team found. Mupirocin is effective in treating contaminated lesions and skin infections, and is widely advocated even when wounds are not contaminated, although there is little evidence...